Given that highly active antiretroviral therapy (HAART) has been demonstrated useful to restore immune competence in type-1 human immunodeficiency virus (HIV-1)-infected subjects, we evaluated the specific antibody response to influenza vaccine in a cohort of HIV-1-infected children on HAART so as to analyze the quality of this immune response in patients under antiretroviral therapy. Sixteen HIV-1-infected children and 10 HIV-1 seronegative controls were immunized with a commercially available trivalent inactivated influenza vaccine containing the strains A/H1N1, A/H3N2, and B. Serum hemagglutinin inhibition (HI) antibody titers were determined for the three viral strains at the time of vaccination and 1 month later. Immunization induced a significantly increased humoral response against the three influenza virus strains in controls, and only against A/H3N2 in HIV-1-infected children. The comparison of post-vaccination HI titers between HIV-1+ patients and HIV-1 negative controls showed significantly higher HI titers against the three strains in controls. In addition, post vaccination protective HI titers (defined as equal to or higher than 1:40) against the strains A/H3N2 and B were observed in a lower proportion of HIV-1+ children than in controls, while a similar proportion of individuals from each group achieved protective HI titers against the A/H1N1 strain. The CD4+ T cell count, CD4/CD8 T cells ratio, and serum viral load were not affected by influenza virus vaccination when pre- vs post-vaccination values were compared. These findings suggest that despite the fact that HAART is efficient in controlling HIV-1 replication and in increasing CD4+ T cell count in HIV-1-infected children, restoration of immune competence and response to cognate antigens remain incomplete, indicating that additional therapeutic strategies are required to achieve a full reconstitution of immune functions.

Download full-text PDF

Source
http://dx.doi.org/10.1590/s0074-02762007005000055DOI Listing

Publication Analysis

Top Keywords

hiv-1-infected children
16
antiretroviral therapy
12
immune response
8
response influenza
8
type-1 human
8
human immunodeficiency
8
immunodeficiency virus
8
highly active
8
active antiretroviral
8
immune competence
8

Similar Publications

Article Synopsis
  • The study focuses on the envelope glycoprotein (Env) of HIV-1, which is essential for the virus's ability to infect host cells and is a key target for vaccines and therapies.
  • Researchers analyzed the genetic characteristics of the Env gene in 145 newly diagnosed HIV-1 patients in Baoding City, successfully sequencing 142 samples and predicting coreceptor usage.
  • Results indicated that 50% of the patients were infected with CCR5-tropic viruses, and specific subtypes showed trends in coreceptor preferences and similarities in the V3 loop's net charges, enhancing insights for vaccine and treatment development.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how co-occurring HIV and tuberculosis (TB) affect the heart's efficiency in adolescents with HIV acquired at birth (APHIV) in Cape Town, South Africa.
  • Researchers hypothesized that APHIV individuals who had previous TB would show worse cardiovascular health due to increased inflammation and disrupted metabolism.
  • Results indicated that APHIV with prior TB had lower cardiac efficiency compared to those without TB, but this was not linked to traditional markers of inflammation or lipid levels, suggesting other factors may be involved.
View Article and Find Full Text PDF

Background: Despite significant reductions in mother-to-child HIV-1 transmission risks due to the advancements and scale-up of antiretroviral therapy (ART), the global burden of HIV-1 drug resistance (HIVDR) in treatment-naive and treatment-experienced children and adolescents remains poorly understood. In this study, we conducted a systematic review and meta-analysis to estimate the prevalence of HIVDR in these populations globally, regionally, and at the country level.

Methods: We systematically searched PubMed, Embase, and Web of Science for studies reporting HIVDR in treatment-naive and treatment-experienced children and adolescents from inception to June 28, 2024.

View Article and Find Full Text PDF

HIV-1 envelope glycoproteins (Env) from primary HIV-1 isolates typically adopt a pretriggered "closed" conformation that resists to CD4-induced (CD4i) non-neutralizing antibodies (nnAbs) mediating antibody-dependent cellular cytotoxicity (ADCC). CD4-mimetic compounds (CD4mcs) "open-up" Env allowing binding of CD4i nnAbs, thereby sensitizing HIV-1-infected cells to ADCC. Two families of CD4i nnAbs, the anti-cluster A and anti-coreceptor binding site (CoRBS) Abs, are required to mediate ADCC in combination with the indane CD4mc BNM-III-170.

View Article and Find Full Text PDF

Discovery of L15 as a novel Vif PROTAC degrader with antiviral activity against HIV-1.

Bioorg Med Chem Lett

October 2024

State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Sichuan, Chengdu 610041, China. Electronic address:

Article Synopsis
  • Viral infectivity factor (Vif) is a promising target for HIV-1 treatments, and researchers have developed a new class of inhibitors that work well against HIV-1 and its drug-resistant strains.
  • Using proteolytic targeting chimera (PROTAC), the study explores how to effectively degrade the Vif protein, which is crucial for the virus's ability to replicate.
  • The compound L15 has shown a dose-dependent ability to degrade Vif and demonstrated antiviral activity, laying the groundwork for future antiviral drug development using PROTACs for HIV/AIDS.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!